Holen Sie sich die Stockscreener-App
59.65
12.55%
-8.56
Handel nachbörslich:
59.60
-0.05
-0.08%
Schlusskurs vom Vortag:
$68.21
Offen:
$55.52
24-Stunden-Volumen:
4.02M
Relative Volume:
2.54
Marktkapitalisierung:
$1.73B
Einnahmen:
$861.31M
Nettoeinkommen (Verlust:
$53.12M
KGV:
34.56
EPS:
1.7262
Netto-Cashflow:
$85.01M
1W Leistung:
-9.07%
1M Leistung:
-38.46%
6M Leistung:
-28.93%
1J Leistung:
-68.10%
1-Tages-Spanne:
$53.11
$64.10
1-Wochen-Bereich:
$53.11
$71.16
52-Wochen-Spanne:
$53.11
$197.75
Inspire Medical Systems Inc Stock (INSP) Company Profile
Firmenname
Inspire Medical Systems Inc
Sektor
Branche
Telefon
763-957-5037
Adresse
5500 WAYZATA BLVD, GOLDEN VALLEY
Compare INSP vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INSP
Inspire Medical Systems Inc
|
59.65 | 1.98B | 861.31M | 53.12M | 85.01M | 1.7262 |
|
ABT
Abbott Laboratories
|
111.47 | 197.52B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
365.85 | 139.09B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
100.88 | 129.59B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.12 | 108.96B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
76.44 | 46.04B | 6.07B | 1.06B | 799.60M | 1.8527 |
Inspire Medical Systems Inc Stock (INSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2026-02-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2026-01-27 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-01-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2026-01-22 | Herabstufung | Truist | Buy → Hold |
| 2025-12-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-26 | Hochstufung | Truist | Hold → Buy |
| 2025-11-25 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-11-24 | Hochstufung | Stifel | Hold → Buy |
| 2025-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-10-24 | Herabstufung | Jefferies | Buy → Hold |
| 2025-09-22 | Herabstufung | UBS | Buy → Neutral |
| 2025-09-02 | Eingeleitet | Evercore ISI | Outperform |
| 2025-08-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-08-05 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-08-05 | Herabstufung | Truist | Buy → Hold |
| 2024-11-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-05-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-04-19 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2024-01-19 | Eingeleitet | Jefferies | Buy |
| 2024-01-02 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-13 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-12-13 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2021-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-12-15 | Herabstufung | Goldman | Buy → Neutral |
| 2020-11-03 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-11-03 | Hochstufung | Oppenheimer | Underperform → Perform |
| 2020-09-22 | Eingeleitet | JP Morgan | Overweight |
| 2020-09-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-06 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-07-15 | Eingeleitet | Goldman | Buy |
| 2020-06-18 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-18 | Eingeleitet | Lake Street | Buy |
| 2020-04-28 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-04-09 | Eingeleitet | Piper Sandler | Overweight |
| 2020-01-28 | Eingeleitet | Oppenheimer | Underperform |
| 2020-01-27 | Eingeleitet | Oppenheimer | Underperform |
| 2019-11-06 | Hochstufung | Berenberg | Sell → Hold |
| 2019-02-05 | Eingeleitet | Dougherty & Company | Buy |
| 2018-11-28 | Eingeleitet | Berenberg | Sell |
| 2018-10-29 | Eingeleitet | Leerink Partners | Outperform |
| 2018-05-29 | Eingeleitet | Guggenheim | Buy |
| 2018-05-29 | Eingeleitet | Stifel | Buy |
| 2018-05-29 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Inspire Medical Systems Inc Aktie (INSP) Neueste Nachrichten
Baird downgrades Inspire Medical stock to Neutral on reimbursement concerns - Investing.com Nigeria
What the FDA’s 2026 Update Means for Wearables - AOL.com
Jefferies Lowers Price Target for INSP, Keeps Hold Rating | INSP Stock News - GuruFocus
Inspire Medical Systems (NYSE:INSP) Price Target Cut to $66.00 by Analysts at Jefferies Financial Group - MarketBeat
Analyst Shagun Singh Maintains Rating for Inspire Medical Systems (INSP) | INSP Stock News - GuruFocus
Inspire Medical: Still A Long Way From A Good Night’s Sleep (NYSE:INSP) - Seeking Alpha
Inspire Medical Systems (INSP) Stock Trades Down, Here Is Why - Finviz
Inspire Medical Systems Lowers FY2026 Revenue Guidance After CMS Coding Clarification, Oppenheimer Says - marketscreener.com
INSP Stock Falls Despite Q4 Earnings Beat, Gross Margin Expands - Yahoo Finance Singapore
Inspire Medical Systems (NYSE:INSP) Shares Gap Down on Analyst Downgrade - MarketBeat
Piper Sandler Lowers Price Target for INSP to $85, Maintains Ove - GuruFocus
INSP: Mizuho Lowers Price Target to $85, Maintains Outperform Ra - GuruFocus
Inspire Medical Systems stock hits 52-week low at $56.17 - Investing.com
INSP Q4 Deep Dive: Reimbursement Uncertainty Shapes Outlook Despite Strong Product Adoption - Finviz
Inspire Medical Systems stock hits 52-week low at $56.17 By Investing.com - Investing.com UK
This Inspire Medical Systems Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga
Truist Cuts Price Target on Inspire Medical Systems to $70 From $96, Keeps Hold Rating - marketscreener.com
Inspire Medical Systems (NYSE:INSP) Given New $85.00 Price Target at Piper Sandler - MarketBeat
Mizuho Has Lowered Expectations for Inspire Medical Systems (NYSE:INSP) Stock Price - MarketBeat
Inspire Medical Systems, Inc. (NYSE:INSP) Q4 2025 earnings call transcript - MSN
Inspire Medical Systems, Inc. (NYSE:INSP) Q4 2025 Earnings Call Transcript - Insider Monkey
RBC Cuts Price Target on Inspire Medical Systems to $68 From $90, Keeps Sector Perform Rating - marketscreener.com
Baird Downgrades Inspire Medical Systems to Neutral From Outperform, Adjusts Price Target to $74 From $130 - marketscreener.com
Piper Sandler lowers Inspire Medical Systems stock price target on reimbursement concerns By Investing.com - Investing.com India
What 19 Analyst Ratings Have To Say About Inspire Medical Systems - Benzinga
Inspire Medical Stock Pre-Market (-8.7%) : Weak 2026 Revenue Guidance - Trefis
Baird Downgrades Inspire Medical Systems (INSP) and Lowers Price Target | INSP Stock News - GuruFocus
Wells Fargo downgrades Inspire Medical Systems stock rating on reimbursement concerns - Investing.com India
Inspire Medical Systems Q4 2025 Earnings Call Transcript - MarketBeat
Inspire Medical Systems (INSP) Reports Strong Q4 Revenue Growth - GuruFocus
Inspire Medical Systems Q4 Earnings Call Highlights - MarketBeat
Inspire Medical (INSP) Q4 2025 Earnings Transcript - AOL.com
Inspire Medical Systems Q4 2025 slides: revenue hits $912M, projects slower growth - Investing.com India
Earnings call transcript: Inspire Medical Systems Q4 2025 Earnings Beat Forecasts - Investing.com
Despite Q4 beats, Inspire Medical declines on revised 2026 revenue outlook - MSN
Inspire Medical Systems (NYSE:INSP) Stock Plunges on Weak 2026 Outlook Despite Q4 Earnings Beat - ChartMill
Inspire Medical Systems earnings beat by $0.97, revenue topped estimates - Investing.com Canada
Inspire Medical Systems (NYSE:INSP) Posts Better-Than-Expected Sales In Q4 CY2025 But Stock Drops - Finviz
Inspire Medical Systems Q4 Earnings, Revenue Rise - marketscreener.com
Inspire Medical Systems (INSP) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
Inspire Medical Updates Governance, Outlines 2026 Growth Outlook - TipRanks
Inspire Medical shares slide 8% as coding change clouds outlook By Investing.com - Investing.com South Africa
Inspire: Q4 Earnings Snapshot - kare11.com
Inspire Medical shares slide 8% as coding change clouds outlook - Investing.com
Inspire: Q4 Financial Results Overview - Bitget
Inspire Medical (INSP) Exceeds Revenue Expectations in Q4 - GuruFocus
INSP Forecasts FY26 Revenue at $950M to $1B - GuruFocus
Inspire Medical Systems (NYSE:INSP) Posts Quarterly Earnings Results - MarketBeat
Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Inspire Medical Systems, Inc. Profit Rises In Q4 - Nasdaq
Inspire Medical Systems: Q4 Earnings Insights - Benzinga
Finanzdaten der Inspire Medical Systems Inc-Aktie (INSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):